Actively Recruiting
Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Led by Qifu Li · Updated on 2024-10-10
97
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
Q
Qifu Li
Lead Sponsor
T
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.
CONDITIONS
Official Title
Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- Diagnosed clearly with primary aldosteronism
- Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) 50 nmol/l
- Willing to undergo surgery
- Adrenal CT or MRI scan showing adrenal nodule ( 1cm)
You will not qualify if you...
- PA patients meeting bypassing AVS criteria (younger than 35 years old, spontaneous hypokalemia, adrenal CT showing unilateral low-density adenoma 1cm, plasma aldosterone >300pg/ml)
- Suspicion of familial hyperaldosteronism or Liddle syndrome (age <20 years, hypertension and hypokalemia, or family history)
- Suspicion of pheochromocytoma or adrenal carcinoma
- Active malignant tumor
- History of adrenalectomy
- Long-term use of glucocorticoids
- Allergy to contrast media preventing AVS
- Pregnant or lactating women; alcohol or drug abuse; mental disorders
- Congestive heart failure NYHA class III or IV; recent serious cardiovascular or cerebrovascular event; severe anemia (Hb<60g/L); serious liver or kidney dysfunction; systemic inflammatory response syndrome; uncontrolled diabetes (FBG 13.3 mmol/L); obesity (BMI 35 kg/m8); untreated aneurysm; other comorbidities interfering with treatment
- Bilateral cortisol hypersecretion conditions such as PBMAH or PPNAD
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affilated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
Q
Qi fu Li, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here